Locations:
June 27, 2024/Innovations

Xealth Launches Dewey, the Industry’s First Performance-based, Digital Health Benchmarking Tool

Cleveland Clinic Innovations portfolio company, Xealth, launches Dewey, which calculates engagement benchmarks from nearly 1000 use cases across more than 400 hospitals.

 Biomedical engineers work inside the BioMEMS and Nanotechnology Labs in the Lerner Building.

Xealth has announced the launch of Dewey, an interactive database that allows its customers to visualize and track the progress of their digital health initiatives. With unique industry insights gained from distributing over 20 million assets and programs to more than five million patients, Xealth aims to help its customers compare their results to industry benchmarks.

Through Dewey, Xealth’s customers can leverage metrics from across health systems to gain useful benchmarks for similar digital health use cases. This allows them to make quick decisions based on patient engagement metrics, such as open rates for emails and SMS, click-through rates, and activation rates.

Xealth's Chief Strategy Officer, Cynthia Church, emphasizes that the platform's findings are statistically relevant due to the significant volume of activity that runs through it. Additionally, Dewey provides guidance by grouping programs into broad categories, such as preventative care, chronic disease management, or surgery preparation, and will soon offer access to real-time charts and additional sub-categories.

Overall, Xealth aims to help its customers address the challenge of measuring the return on investment of digital health by providing them with a basis for comparison and an idea of what engagement should be on a relative basis, thereby enabling them to optimize the performance of their digital health programs.

Read the full press release via GlobeNewswire.

Subscribe to Cleveland Clinic Innovations' Newsletter

Follow Cleveland Clinic Innovations on LinkedIn

Latest from the Newsroom

Artist's illustration of gene editing

Cleveland Clinic First-in-Human Trial Shows Gene-Silencing Therapy for High Cholesterol to Be Safe and Effective

Medical illustration of lipoprotein(a) molecule

Cleveland Clinic Trial Shows Novel Lipoprotein(a) Drug Did Not Reduce Major Cardiovascular Events After Nearly 5 Years

Ali Aminian, M.D., performing bariatric surgery.

Cleveland Clinic Study Finds Bariatric Surgery Effective for Substantial Weight Loss After GLP-1 Intolerance or Limited Weight Loss

Eric Boose, M.D., uses AI software to document a patient appointment.

Newsweek Ranks Cleveland Clinic Among World's Best Smart Hospitals

Graphic representing cardiomyopathy and DNA

Cleveland Clinic-led Study Establishes Major Genetic Contributor to Heart Failure in People of African Ancestry

Dr Fujiki performing surgery

Cleveland Clinic First in Ohio to Perform Abdominal Tumor Removal Using Highly Specialized Surgical Technique

UFC, Cleveland Clinic logos

UFC®, Cleveland Clinic Renew Longstanding Partnership

Panelists at Cleveland Clinic's London Innovation Summit

Cleveland Clinic Holds Second Annual London Innovation Summit